What should Europe require before hospital AI becomes routine?
A same-day report from Europe’s science and medical academies argues that health AI needs evidence suited to changing systems, interoperable data, accountable regulation and a workforce able to challenge the technology—not simply more pilots.
The short version
- What happened
- The 30 September report was produced by a 22-member working group from across Europe; it synthesises evidence and policy rather than reporting a new patient trial.
- Who it affects
- Patients could gain safer and more consistent access to useful AI, but only if local validation, transparency and routes to challenge a decision are real.
- What remains unproven
- This is an expert evidence and policy report, not a new clinical trial; it does not provide a patient sample or a new effect estimate for a specific technology.
Keep in mind
This is an expert evidence and policy report, not a new clinical trial; it does not provide a patient sample or a new effect estimate for a specific technology.
The working group’s 22 members span Europe, but the report is designed for European institutions and health systems rather than every regulatory and care context worldwide.
Implementation details will depend on later guidance, procurement practice, enforcement and the quality of post-market evidence.
Source analysis · 2 linked sources. Primary analysed source date: 30 September 2026.
Read the full report · 6 min The evidence, methods, implications and limitations
The report asks a system question, not a model question
A joint report published on 30 September by the European Academies’ Science Advisory Council and the Federation of European Academies of Medicine asks how AI-enabled health products and services can be evaluated and integrated safely across Europe. The work began in 2024 and was written by a 22-member working group drawn from European science and medical academies. Its announced scope covers evidence generation, regulation, data interoperability, privacy, transparency, explainability, equitable access and the education of the health workforce.
That scope matters because a high-performing model is only one component of care. A hospital also has to decide which patients the tool applies to, whether local data resemble the development data, how outputs enter clinical work, who can override them and what happens after an error or model update. The report is therefore an expert evidence and policy assessment, not a clinical trial. It supplies a framework for public decisions; it does not provide a new patient denominator or a fresh estimate of diagnostic benefit.[1][2]
Evidence must follow a changing intervention
The academies explicitly consider both randomised and pragmatic trial designs. Randomisation can test whether an AI-supported pathway improves a defined outcome under controlled conditions. Pragmatic evaluation can show whether the result survives real staffing, incomplete records, different hospitals and ordinary patient populations. Health AI also creates a lifecycle problem: performance may change when software, data, clinical pathways or the population changes. A single pre-market study cannot answer every post-deployment question.
The practical implication is continuous evidence with pre-agreed stopping and review rules. Hospitals need a baseline against current care, clinically meaningful outcomes, subgroup analysis, workload and cost measures, and monitoring for drift after deployment. A lower error rate on a retrospective dataset is useful, but it is not equivalent to fewer missed diagnoses, safer treatment or better access. Procurement should make vendors disclose the intended population, update policy, known failure modes and evidence for claims made in the local setting.[1][2]
Europe’s rules overlap at the bedside
The report places health AI within several connected European frameworks: the Medical Device Regulation, the AI Act, the European Health Data Space and the Product Liability Directive. Each addresses a different part of the problem. Device rules concern safety and performance; the AI Act adds obligations for high-risk systems; the data space affects access and reuse of health data; and liability rules shape responsibility when products cause harm. A hospital cannot treat compliance with one instrument as proof that the whole care pathway is safe.
Responsibility must remain legible to patients and staff. People need to know when AI materially influences care, how to question a result and where to seek redress. Clinicians need authority to reject an output without being penalised by workflow design. Managers need named owners for validation, monitoring and incident response. Regulators and health systems also need compatible reporting so the same failure is not rediscovered separately in multiple hospitals or countries.[1][2]
Interoperability, equity and skills decide whether value reaches patients
Fragmented records and incompatible formats can turn a promising system into extra clerical work or unsafe missing context. Interoperability is therefore not a technical afterthought: it determines whether relevant information arrives in time and whether performance can be compared across sites. Data governance must also protect sensitive records while making legitimate evaluation possible. Representative data do not guarantee equitable outcomes, but opaque gaps make inequity harder to detect and correct.
Workforce preparation is equally concrete. Staff need enough digital and statistical literacy to recognise unsuitable inputs, automation bias and plausible-looking errors. Training should include the local tool’s limits and escalation route, not only generic AI awareness. Patients and carers should be involved in design and evaluation, particularly when systems affect access, triage or consent. Without those capabilities, a hospital may formally deploy AI while transferring hidden review work and risk to already stretched teams.[1][2]
What would change our assessment
The report is a timely, methods-aware policy synthesis from European academies, but it should not be read as proof that any particular system is safe or cost-effective. Our confidence would strengthen if European institutions translate the recommendations into interoperable evaluation protocols, public post-market incident reporting and procurement clauses that preserve access to validation data and update histories. Multi-country prospective studies should test outcomes, workload and equity across different health systems.
The assessment would weaken if implementation becomes a checklist exercise, if post-deployment monitoring remains proprietary, or if hospitals are expected to absorb model updates without renewed validation. The central question is not whether Europe can approve more AI products. It is whether patients can see sustained benefit, staff can challenge the technology and institutions can detect and correct harm across the full life of a system.[1][2]